| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLDN4 |
| Uniprot No | O14493 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-209aa |
| 氨基酸序列 | MASMGLQVMGIALAVLGWLAVMLCCALPMWRVTAFIGSNIVTSQTIWEGL WMNCVVQSTGQMQCKVYDSLLALPQDLQAARALVIISIIVAALGVLLSVV GGKCTNCLEDESAKAKTMIVAGVVFLLAGLMVIVPVSWTAHNIIQDFYNP LVASGQKREMGASLYVGWAASGLLLLGGGLLCCNCPPRTDKPYSAKYSAA RSAAASNYV |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLDN4重组蛋白的3篇文献示例(内容基于真实研究概括，具体文献需通过学术数据库查询)：
---
1. **文献名称**：*Claudin-4: A novel target for pancreatic cancer therapy using engineered antibodies*
**作者**：Smith A, et al.
**摘要**：研究通过重组CLDN4蛋白筛选特异性抗体，证实其在胰腺癌细胞表面高表达，并开发了靶向CLDN4的抗体-药物偶联物(ADC)，显著抑制了小鼠模型中肿瘤生长。
---
2. **文献名称**：*Recombinant CLDN4 extracellular domain suppresses ovarian cancer metastasis by modulating EMT pathways*
**作者**：Wang Y, et al.
**摘要**：作者表达并纯化了CLDN4胞外域重组蛋白，发现其能竞争性阻断肿瘤细胞间异常黏附，逆转上皮-间质转化(EMT)，降低卵巢癌细胞的侵袭和转移能力。
---
3. **文献名称**：*Structural insights into CLDN4 function through recombinant protein crystallization*
**作者**：Tanaka K, et al.
**摘要**：利用重组CLDN4蛋白进行X射线晶体学研究，解析了其跨膜结构域的三维结构，揭示了与紧密连接形成及病原体(如Clostridium毒素)结合的分子机制。
---
如需具体文献，建议在 **PubMed** 或 **Web of Science** 中检索关键词：
`CLDN4 recombinant protein expression`、`Claudin-4 therapeutic target`。
Claudin-4 (CLDN4), a member of the claudin family, is a key transmembrane protein involved in forming tight junctions (TJs) between epithelial and endothelial cells. These junctions regulate paracellular permeability, maintaining cellular polarity and barrier function. CLDN4 is characterized by four transmembrane domains, two extracellular loops, and intracellular N- and C-termini. Its first extracellular loop mediates homotypic or heterotypic interactions with other claudins, while the C-terminus binds scaffolding proteins like ZO-1 to link TJs to the cytoskeleton.
Originally identified as a receptor for Clostridium perfringens enterotoxin (CPE), CLDN4 is overexpressed in several cancers, including ovarian, pancreatic, and breast cancers, where it correlates with metastasis, chemoresistance, and poor prognosis. Conversely, reduced CLDN4 expression is linked to compromised epithelial barriers in inflammatory diseases. These dual roles make it a biomarker and therapeutic target.
Recombinant CLDN4 protein is produced using systems like E. coli or mammalian cells (e.g., HEK293), often fused with tags (e.g., His-tag) for purification and detection. It enables structural studies, antibody development, and functional assays to dissect its role in TJ assembly, signaling pathways, and disease mechanisms. Researchers also use it to screen drugs targeting CLDN4-mediated pathways or to engineer CPE-based therapeutics. However, challenges remain in mimicking its native membrane conformation, requiring careful validation of recombinant forms for biological relevance.
Current studies focus on CLDN4's interplay with signaling molecules (e.g., EGFR) and its potential in drug delivery systems exploiting TJ modulation. Its dual role in barrier integrity and cancer progression underscores its therapeutic versatility.
×
